Literature DB >> 21988135

Antibacterial spectrum and cytotoxic activities of serrulatane compounds from the Australian medicinal plant Eremophila neglecta.

O F Anakok1, C P Ndi, M D Barton, H J Griesser, S J Semple.   

Abstract

AIMS: To determine the antibacterial spectrum and cytotoxic activities of serrulatane compounds from the Australian plant Eremophila neglecta. METHODS AND
RESULTS: Antimicrobial activities of serrulatane compounds 8,19-dihydroxyserrulat-14-ene (1) and 8-hydroxyserrulat-14-en-19-oic acid (2) were tested against Gram-negative and Gram-positive bacteria including human and veterinary pathogens and some multidrug-resistant isolates. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of the compounds were determined by broth microdilution assay. Both compounds exhibited antibacterial activity against all Gram-positive test strains. They showed antimycobacterial activity against isolates of Mycobacterium fortuitum and Mycobacterium chelonae. Of the five Gram-negative bacteria tested, only Moraxella catarrhalis showed susceptibility to the compounds. Cytotoxic activities were tested in the Vero cell line. Compound 1 showed more activity than 2 in both antibacterial and cytotoxicity assays with cytotoxicity at concentrations similar to the MBC.
CONCLUSIONS: Serrulatane compounds showed significant activity against medically important bacteria, with 1 exhibiting stronger antibacterial activity. However, they also displayed toxicity to mammalian cells. SIGNIFICANCE AND IMPACT OF THE STUDY: Serrulatanes are of interest as novel antibacterial compounds for use in biomedical applications; this study reports data obtained with a range of bacterial strains and mammalian cells, essential for assessing the capabilities and limitations of potential applicability of these compounds.
© 2011 The Authors. Journal of Applied Microbiology © 2011 The Society for Applied Microbiology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21988135     DOI: 10.1111/j.1365-2672.2011.05174.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  6 in total

1.  In Vitro Study to Evaluate Antibacterial and Non-haemolytic Activities of Four Iranian Medicinal Plants.

Authors:  S Sepahi; A Ghorani-Azam; S Sepahi; A Asoodeh; S Rostami
Journal:  West Indian Med J       Date:  2014-02-24       Impact factor: 0.171

2.  Broadly Applicable Stereoselective Syntheses of Serrulatane, Amphilectane Diterpenes, and Their Diastereoisomeric Congeners Using Asymmetric Hydrovinylation for Absolute Stereochemical Control.

Authors:  Srinivasarao Tenneti; Souvagya Biswas; Glen Adam Cox; Daniel J Mans; Hwan Jung Lim; T V RajanBabu
Journal:  J Am Chem Soc       Date:  2018-07-27       Impact factor: 15.419

Review 3.  Ethnobotany and the Role of Plant Natural Products in Antibiotic Drug Discovery.

Authors:  Gina Porras; François Chassagne; James T Lyles; Lewis Marquez; Micah Dettweiler; Akram M Salam; Tharanga Samarakoon; Sarah Shabih; Darya Raschid Farrokhi; Cassandra L Quave
Journal:  Chem Rev       Date:  2020-11-09       Impact factor: 60.622

4.  Diterpenes Synthesized from the Natural Serrulatane Leubethanol and Their in Vitro Activities against Mycobacterium tuberculosis.

Authors:  Ricardo Escarcena; Jonathan Perez-Meseguer; Esther Del Olmo; Blanca Alanis-Garza; Elvira Garza-González; Ricardo Salazar-Aranda; Noemí Waksman de Torres
Journal:  Molecules       Date:  2015-04-21       Impact factor: 4.411

Review 5.  Efficacy and Mechanisms of Flavonoids against the Emerging Opportunistic Nontuberculous Mycobacteria.

Authors:  Suresh Mickymaray; Faiz Abdulaziz Alfaiz; Anand Paramasivam
Journal:  Antibiotics (Basel)       Date:  2020-07-27

6.  The biosynthesis of the anti-microbial diterpenoid leubethanol in Leucophyllum frutescens proceeds via an all-cis prenyl intermediate.

Authors:  Garret P Miller; Wajid Waheed Bhat; Emily R Lanier; Sean R Johnson; Davis T Mathieu; Björn Hamberger
Journal:  Plant J       Date:  2020-08-28       Impact factor: 6.417

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.